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Statement of translational relevance
Immune checkpoint inhibitors are approved or in advanced development for several types of cancer. To expand the clinical benefit of this approach, agents designed to target other immunoregulatory receptors are under clinical evaluation, including agonist antibodies against co-stimulatory molecules such as CD137. The manuscript reports safety, tolerability, and pharmacodynamic activity data from three studies evaluating urelumab, an agonist anti-CD137 monoclonal antibody, and includes information on the hepatotoxicity observed. The data showed that urelumab dose was the single most important factor contributing to the development of severe transaminitis, with significant transaminitis strongly associated with doses ≥1 mg/kg. In addition, 
INTRODUCTION
Agents designed to block the inhibitory immune checkpoints cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1) are approved for advanced melanoma (alone and in combination), and anti-PD-1 is approved for non-small cell lung cancer and renal cell carcinoma (1) . Both anti-CTLA-4 and anti-PD-1 can elicit durable clinical responses and, in some patients, result in long-term remissions with no clinical evidence of cancer (2) (3) (4) . To expand the clinical benefit of this approach, agents designed to target other immunoregulatory pathways are under evaluation, including antagonists of inhibitory checkpoints such as LAG-3 and TIM-3, but also agonist antibodies against co-stimulatory molecules on immune cells such as CD137 (4-1BB), CD40, GITR, and OX-40 (5-7).
CD137 is a co-stimulatory member of the tumor necrosis factor (TNF) receptor superfamily that is expressed on a variety of immune cells following activation, including T cells, dendritic cells, and natural killer cells. Signaling via CD137 can lead to cytokine induction, prevention of activation-induced cell death, and upregulation of cytotoxic T-cell activity; CD137 may also reduce the infiltration of regulatory T cells into tumors (8, 9) . Melero and colleagues were the first to report that agonist monoclonal antibodies (mAbs) to CD137 eradicated large, established tumors in mice. The long-lasting antitumor activity seen in their model was primarily mediated by CD8 + T cells and associated with memory responses (10) .
Two mAbs to CD137 have been developed and are undergoing clinical evaluation.
Urelumab (BMS-663513, clone 10C7; Bristol-Myers Squibb) is an agonist, nonligand-blocking, fully human mAb, engineered as an IgG4 to reduce binding to Fc receptors with a hinge mutation (S228P) to improve stability (11) (12) (13) . PF-05082566
(Pfizer) is a fully human IgG2 mAb (14) . In preclinical studies, urelumab enhanced interferon gamma (IFN-γ) production, T-cell survival, and the cytolytic activity of antigen-specific T cells (11, 13, 15) , as expected for an antibody with co-stimulatory
Research. Subsequently, three urelumab-based combination studies were opened from March 2013 onward.
Here we report integrated safety and preliminary pharmacodynamic data from urelumab monotherapy studies CA186-001 (NCT00309023), CA186-006 (NCT00612664), and CA186-011 (NCT01471210).
PATIENTS AND METHODS
Patients and Study Design
Aggregated data from patients participating in three urelumab studies were included in this analysis. For all studies, patients provided written, informed consent; protocols were approved by the relevant institutional review boards and independent ethics committees; and conduct was in accordance with International Conference on Harmonization guidelines on Good Clinical Practice and the principles of the Declaration of Helsinki. 
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objective was to assess safety and tolerability of urelumab, and secondary objectives included assessing pharmacokinetics (PK), relationship between dose and biologic effect, and antitumor activity (11) .
Study CA186-006 (-006) was a randomized, multidose, open-label, parallel 4-arm, phase 2 study in patients with stage III/IV melanoma who had received one line of prior systemic treatment with any regimen (nonexperimental or experimental) and relapsed, progressed, or did not tolerate that regimen. Patients were randomized to receive urelumab at 0.1, 1, or 5 mg/kg Q3W or 1 mg/kg every 6 weeks (Q6W). The primary objective was to determine the 6-month progression-free survival rate in each arm. Secondary objectives included assessment of the tumor response rate, safety profile, and PK and pharmacodynamic parameters.
Study CA186-011 (-011) is an ongoing phase 1 study that included dose escalation (part 1) using a 6 + 9 design, cohort expansion (part 2), and tumor-specific cohort expansion (part 3). In part 1, successive cohorts of patients with advanced and/or metastatic solid tumors were treated as follows: cohort 1 with 0.1 mg/kg Q3W and cohort 2 with 0.3 mg/kg Q3W. In part 2, both cohorts (1 + 2) were expanded to 20 patients with advanced solid tumors. In part 3, additional tumor-specific cohorts with B-cell non-Hodgkin's lymphoma, colorectal cancer, and head and neck cancer (10 patients each) were enrolled at the highest tolerated dose of 0.3 mg/kg Q3W.
The primary objective was to evaluate safety and define dose-limiting toxicity and maximum tolerated dose of urelumab; secondary objectives included assessment of preliminary antitumor activity, PK, and immunogenicity.
Assessments
In all studies, safety was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (v3.0 in -001 and -006, and v4 in -011).
Adverse events (AEs) were mapped to preferred term and body system using the Medical Dictionary for Regulatory Activities. Safety assessments were based on Tables   1 and 2 ). Blood samples for pharmacodynamic assessments were collected at prespecified time points from consenting patients (n = 32).
Data Analysis
All patients treated in studies -001 and -006 were included in the analysis, as well as 
RESULTS
Patient Characteristics
Between 2005 and 2008, 115 patients were enrolled and treated in -001; 159 patients were enrolled into -006, 158 of whom received urelumab; and between 2011 and 2014, 73 patients were enrolled and treated in -011. Baseline demographics for all enrolled patients (N = 347) are shown ( Table 1) .
Overview of Treatment-Related AEs
Across all studies, urelumab doses between 1 and 15 mg/kg resulted in a higher frequency of treatment-related AEs than doses of 0.1 or 0.3 mg/kg ( Table 2) . At doses ≥1 mg/kg, the most frequent treatment-related AEs were increased AST (27%), increased ALT (27%), and fatigue (24%), although there was no evidence of dose dependency. At 0.3 mg/kg, increased AST and fatigue were the most frequent treatment-related AEs (both 14%), and at 0.1 mg/kg, fatigue (16%) and nausea (13%) were the most common treatment-related AEs. Grade 3 or higher treatmentrelated AEs were more frequent at urelumab doses of 1 to 15 mg/kg than at the 0.1 and 0.3 mg/kg doses ( Table 2) .
There was a similar pattern for treatment-related SAEs, with the majority occurring at doses ≥1 mg/kg and the most common being increased ALT, increased AST, and fatigue ( Table 2 ). At 0.3 mg/kg there were 7 treatment-related SAEs (2 increased ALT, 2 increased AST, 1 abnormal LFT, 1 acute hepatitis, and 1 enteritis). There were 2 treatment-related SAEs at 0.1 mg/kg: increased ALT and erysipelas ( Table   2 ).
The rate of patient discontinuation due to a treatment-related AE was higher with urelumab ≥1 mg/kg compared with 0.1 and 0.3 mg/kg. At ≥1 mg/kg, 37 of 229 patients (16%) discontinued due to a treatment-related AE; at 0.3 mg/kg, 5 of 56 patients (9%) discontinued; and at 0.1 mg/kg, 7 of 61 patients (11%) discontinued.
Two deaths occurred at the higher dose range (1 and 5 mg/kg, respectively). Both deaths were attributed to drug-related hepatotoxicity and the patients were enrolled in study -006 in the 1 mg/kg Q3W and 5 mg/kg Q3W arms, respectively. Neither patient was taking concomitant medications with known potential for hepatotoxicity, and both received immunosuppressant medication for management. Postmortem examination was conducted in only 1 of the 2 patients and was noncontributory. One Of note, the patient in the 1 mg/kg Q3W arm had previously been treated with a monoclonal antibody to CTLA-4 and had developed one immune-related AE, panhypopituitarism, while on prior treatment with CTLA-4 blockade.
Transaminitis
Transaminitis was more frequent at urelumab doses ≥1 mg/kg ( Table 3) 
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DISCUSSION
The co-stimulatory receptor CD137 is a promising target for cancer immunotherapy (8, 9) . This integrated safety analysis is one of the first reports of an agonist mAb targeting CD137. Overall safety data from evaluation of urelumab at doses of 0.1 to 15 mg/kg across three studies support 0.1 mg/kg Q3W as the maximum tolerated dose. Experience with urelumab at 0.1 mg/kg Q3W in 61 patients with advanced malignancies demonstrated acceptable safety and tolerability, and pharmacodynamic activity consistent with immune activation. The significant transaminitis that led to the suspension of the clinical program was strongly associated with exposure to urelumab at doses of 1 mg/kg and above, suggesting a reasonable separation between the potential efficacious dose and the doses associated with toxicity. Doses ≥1 mg/kg were associated with a high incidence of moderate to severe hepatic toxicity (ranging from asymptomatic increases in laboratory measures of LFTs to hepatic failure). Outcomes from analysis of LFTs and hepatic AEs showed that transaminitis was strongly associated with exposure to urelumab ≥1 mg/kg. In contrast, doses <1 mg/kg Q3W were associated with the lowest probability of severe transaminitis and generally a low frequency of other AEs-predominantly grade 1 or No risk factor predisposing patients to developing transaminitis was identified in the integrated safety analysis of the completed studies -001 and -006 (n = 169). Although the evaluation of data from study -011 is ongoing, preliminary evaluation is similarly consistent with no identifiable risk factor for transaminitis.
Most of the patients who had their treatment withheld because of grade 2 transaminitis were able to resume treatment at the same dose with no recurrence of these AEs. Experience gained managing transaminitis in studies -001, -006, and -011, and in managing transaminitis induced by other immune checkpoint inhibitors, contributed to the development of the management strategies included in current urelumab study protocols. In general, patients receiving urelumab require close monitoring of LFTs. For grade 2 LFT AEs, urelumab dosing was delayed, alternative causes were investigated, and LFTs were monitored at increased frequency; for grade 3 or 4 AEs or grade 2 events that were worsening or persisting for more than 5 to 7 days, urelumab was discontinued, LFTs were monitored at increased frequency, and corticosteroids were administered.
Observations in murine models provide a possible explanation for liver-related AEs associated with agonist CD137 mAbs. Liver lymphocyte infiltration was reported in several studies of mice treated with a mouse anti-CD137 mAb (17) (18) (19) . While preliminary data from preclinical toxicity models suggest hepatic infiltration by lymphocytes (following crosslinking of CD137 receptor) as being possibly involved in producing liver toxicity, additional preclinical studies are ongoing to further address the mechanism of action of urelumab-related AEs (Bristol-Myers Squibb, unpublished data).
Aside from transaminitis, urelumab was not associated with the immune-mediated AEs commonly reported with CTLA-4 and PD-1/PD-L1 immune checkpoint inhibitors that affect the gastrointestinal, skin, pulmonary, and endocrine systems (20) . inhibitors (20) , was observed with urelumab. Drug-related febrile neutropenia was not noted at the urelumab maximum tolerated dose.
Although the mechanism of urelumab-related neutropenia is a matter of ongoing investigation, data from a murine model of listeria showed that CD137-mediated stimulation of neutrophils in early infection caused rapid production of inflammatory cytokines/chemokines and subsequent infiltration of neutrophils and monocytes crucial for eliminating the infecting bacteria (21) .
The clinical evaluation of urelumab is ongoing at 0.1 mg/kg Q3W as monotherapy and in combination with targeted mAbs, cetuximab, rituximab, or elotuzumab (NCT01775631, NCT02110082, and NCT02252263). This approach is based on preclinical data that showed enhancement of antibody-dependent cellular cytotoxicity when an agonist CD137 mAb was given after a targeted mAb (22) (23) (24) . A study is also in progress to evaluate urelumab in combination with nivolumab, an anti-PD-1 immune checkpoint inhibitor, in patients with advanced solid tumors and B-cell nonHodgkin's lymphoma (NCT02253992). Preclinical data suggest that combined targeting of co-stimulatory and inhibitory immune checkpoint pathways may enhance antitumor immune responses and prolong survival, and could reduce the incidence of immune-mediated AEs, including liver inflammation (17, (25) (26) (27) ).
In summary, urelumab at 0.1 mg/kg Q3W is well tolerated with evidence of immunologic activity. Clinical studies evaluating urelumab as monotherapy and in combination with other immuno-oncology agents are ongoing.
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